RATIONALE: Alveolar transforming growth factor (TGF)-β1 signaling and expression of TGF-β1 target genes are increased in patients with idiopathic pulmonary fibrosis (IPF) and in animal models of pulmonary fibrosis. Internalization and degradation of TGF-β receptor TβRI inhibits TGF-β signaling and could attenuate development of experimental lung fibrosis. OBJECTIVES: To demonstrate that after experimental lung injury, human syndecan-2 confers antifibrotic effects by inhibiting TGF-β1 signaling in alveolar epithelial cells. METHODS: Microarray assays were performed to identify genes differentially expressed in alveolar macrophages of patients with IPF versus control subjects. Transgenic mice that constitutively overexpress human syndecan-2 in macrophages were developed to test the antifibrotic properties of syndecan-2. In vitro assays were performed to determine syndecan-2-dependent changes in epithelial cell TGF-β1 signaling, TGF-β1, and TβRI internalization and apoptosis. Wild-type mice were treated with recombinant human syndecan-2 during the fibrotic phase of bleomycin-induced lung injury. MEASUREMENTS AND MAIN RESULTS: We observed significant increases in alveolar macrophage syndecan-2 levels in patients with IPF. Macrophage-specific overexpression of human syndecan-2 in transgenic mice conferred antifibrotic effects after lung injury by inhibiting TGF-β1 signaling and downstream expression of TGF-β1 target genes, reducing extracellular matrix production and alveolar epithelial cell apoptosis. In vitro, syndecan-2 promoted caveolin-1-dependent internalization of TGF-β1 and TβRI in alveolar epithelial cells, which inhibited TGF-β1 signaling and epithelial cell apoptosis. Therapeutic administration of human syndecan-2 abrogated lung fibrosis in mice. CONCLUSIONS: Alveolar macrophage syndecan-2 exerts antifibrotic effects by promoting caveolin-1-dependent TGF-β1 and TβRI internalization and inhibiting TGF-β1 signaling in alveolar epithelial cells. Hence, molecules that facilitate TβRI degradation via endocytosis represent potential therapies for pulmonary fibrosis.
RATIONALE: Alveolar transforming growth factor (TGF)-β1 signaling and expression of TGF-β1 target genes are increased in patients with idiopathic pulmonary fibrosis (IPF) and in animal models of pulmonary fibrosis. Internalization and degradation of TGF-β receptor TβRI inhibits TGF-β signaling and could attenuate development of experimental lung fibrosis. OBJECTIVES: To demonstrate that after experimental lung injury, humansyndecan-2 confers antifibrotic effects by inhibiting TGF-β1 signaling in alveolar epithelial cells. METHODS: Microarray assays were performed to identify genes differentially expressed in alveolar macrophages of patients with IPF versus control subjects. Transgenic mice that constitutively overexpress humansyndecan-2 in macrophages were developed to test the antifibrotic properties of syndecan-2. In vitro assays were performed to determine syndecan-2-dependent changes in epithelial cell TGF-β1 signaling, TGF-β1, and TβRI internalization and apoptosis. Wild-type mice were treated with recombinant humansyndecan-2 during the fibrotic phase of bleomycin-induced lung injury. MEASUREMENTS AND MAIN RESULTS: We observed significant increases in alveolar macrophage syndecan-2 levels in patients with IPF. Macrophage-specific overexpression of humansyndecan-2 in transgenic mice conferred antifibrotic effects after lung injury by inhibiting TGF-β1 signaling and downstream expression of TGF-β1 target genes, reducing extracellular matrix production and alveolar epithelial cell apoptosis. In vitro, syndecan-2 promoted caveolin-1-dependent internalization of TGF-β1 and TβRI in alveolar epithelial cells, which inhibited TGF-β1 signaling and epithelial cell apoptosis. Therapeutic administration of humansyndecan-2 abrogated lung fibrosis in mice. CONCLUSIONS: Alveolar macrophage syndecan-2 exerts antifibrotic effects by promoting caveolin-1-dependent TGF-β1 and TβRI internalization and inhibiting TGF-β1 signaling in alveolar epithelial cells. Hence, molecules that facilitate TβRI degradation via endocytosis represent potential therapies for pulmonary fibrosis.
Authors: Carol A Feghali-Bostwick; Christopher G Tsai; Vincent G Valentine; Stephen Kantrow; Michael W Stoner; Joseph M Pilewski; Aneal Gadgil; M Patricia George; Kevin F Gibson; Augustine M K Choi; Naftali Kaminski; Yingze Zhang; Steven R Duncan Journal: J Immunol Date: 2007-08-15 Impact factor: 5.422
Authors: Ping Ren; Ivan O Rosas; Sandra D Macdonald; Hai-Ping Wu; Eric M Billings; Bernadette R Gochuico Journal: Am J Respir Crit Care Med Date: 2007-03-01 Impact factor: 21.405
Authors: Kiichi Nakahira; Hong Pyo Kim; Xue Hui Geng; Atsunori Nakao; Xue Wang; Noriko Murase; Peter F Drain; Xiaomei Wang; Madhu Sasidhar; Elizabeth G Nabel; Toru Takahashi; Nicholas W Lukacs; Stefan W Ryter; Kiyoshi Morita; Augustine M K Choi Journal: J Exp Med Date: 2006-09-25 Impact factor: 14.307
Authors: Konstantin Tsoyi; Juan C Osorio; Sarah G Chu; Isis E Fernandez; Sergio Poli De Frias; Lynette Sholl; Ye Cui; Carmen S Tellez; Jill M Siegfried; Steven A Belinsky; Mark A Perrella; Souheil El-Chemaly; Ivan O Rosas Journal: Am J Respir Cell Mol Biol Date: 2019-06 Impact factor: 6.914
Authors: Sarah G Chu; Julian A Villalba; Xiaoliang Liang; Kevin Xiong; Konstantin Tsoyi; Bonna Ith; Ehab A Ayaub; Raju V Tatituri; Derek E Byers; Fong-Fu Hsu; Souheil El-Chemaly; Edy Y Kim; Yuanyuan Shi; Ivan O Rosas Journal: Am J Respir Cell Mol Biol Date: 2019-12 Impact factor: 6.914
Authors: Christina M Termini; Amara Pang; Michelle Li; Tiancheng Fang; Vivian Y Chang; John P Chute Journal: Blood Date: 2022-01-13 Impact factor: 22.113
Authors: Alexandra L McCubbrey; Lea Barthel; Michael P Mohning; Elizabeth F Redente; Kara J Mould; Stacey M Thomas; Sonia M Leach; Thomas Danhorn; Sophie L Gibbings; Claudia V Jakubzick; Peter M Henson; William J Janssen Journal: Am J Respir Cell Mol Biol Date: 2018-01 Impact factor: 6.914
Authors: Konstantin Tsoyi; Sarah G Chu; Nasly G Patino-Jaramillo; Julie Wilder; Julian Villalba; Melanie Doyle-Eisele; Jacob McDonald; Xiaoli Liu; Souheil El-Chemaly; Mark A Perrella; Ivan O Rosas Journal: Am J Respir Cell Mol Biol Date: 2018-02 Impact factor: 6.914
Authors: Konstantin Tsoyi; Xiaoliang Liang; Giulia De Rossi; Stefan W Ryter; Kevin Xiong; Sarah G Chu; Xiaoli Liu; Bonna Ith; Lindsay J Celada; Freddy Romero; Matthew J Robertson; Anthony J Esposito; Sergio Poli; Souheil El-Chemaly; Mark A Perrella; YuanYuan Shi; James Whiteford; Ivan O Rosas Journal: Am J Respir Crit Care Med Date: 2021-08-01 Impact factor: 30.528